Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|December 8, 2021

Supplements and Featured Publications

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone
Volume 27
Issue 20

eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

Author(s)Linda F. Fried, MD, MPH, Natalia Petruski-Ivleva, PhD, Kerstin Folkerts, MSc

Supplementary Appendix

Download PDF

Articles in this issue

over 4 years ago

Article

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone - Participating Faculty

over 4 years ago

Article

ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

over 4 years ago

Article

Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes

over 4 years ago

Article

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

over 4 years ago

Article

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

wooden block for health, medicine, insurance, healthcare concept | Image credit: ภัทรชัย รัตนชัยวงค์ - stock.adobe.com

CKD Stage, Proteinuria Tied to Higher HCRU in IgAN

ByLaura Joszt, MA

June 15th 2026

AJMC original research policy

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Thai Dang, MD

Post-AKI Monitoring Gaps Risk Long-Term CKD: Thai Dang, MD

ByLaura Joszt, MA,Thai Dang, MD

June 12th 2026

AJMC original research clinical

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

AJMC original research managerial

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Trending on AJMC

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Defunding Co-Payment Assistance Disrupted nAMD Care

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer